Kazia Therapeutics Files 20-F for FY24

TL;DR

Kazia Therapeutics (KZA) dropped its 20-F for FY24 - check financials for the latest.

AI Summary

Kazia Therapeutics Ltd. filed its annual 20-F report for the fiscal year ending June 30, 2024. The company, formerly Novogen Ltd., is based in Sydney, NSW, Australia, and operates in the pharmaceutical preparations sector. The filing details financial statements and equity changes for the fiscal years 2022, 2023, and 2024.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Kazia Therapeutics' financial health and operational status for the past fiscal year, crucial for understanding the company's performance and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Kazia Therapeutics is subject to inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.

Key Numbers

• 2024-06-30 — Fiscal Year End (Reporting period for the 20-F filing.)
• 2023-06-30 — Previous Fiscal Year End (Comparative financial data available.)
• 2022-06-30 — Prior Fiscal Year End (Further comparative financial data available.)

Key Players & Entities

• KAZIA THERAPEUTICS LTD (company) — Filer
• NOVOGEN LTD (company) — Former company name
• THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW 2000 (location) — Business and Mail Address
• 0001075880 (company_id) — Central Index Key
• 2834 (industry_code) — Standard Industrial Classification (Pharmaceutical Preparations)
• 0630 (date) — Fiscal Year End

FAQ

Key Financial Figures

• $25.0 m — nt revenue. We have incurred losses of A$25.0 million, A$20.5 million, and A$26.8 milli
• $20.5 m — ave incurred losses of A$25.0 million, A$20.5 million, and A$26.8 million for the fisca
• $26.8 million — of A$25.0 million, A$20.5 million, and A$26.8 million for the fiscal years ended 30 June 2022
• $2.3 million — respectively. We generated revenues of A$2.3 million during 2024 from the licensing of our d
• $115.1 million — une 2024, we had accumulated losses of A$115.1 million. We have devoted most of our financial
• $4.6 million — the year ended 30 June 2024 we raised A$4.6 million from the sale of ADSs. We will need to
• $1.7 million — 24, we had cash on hand at the bank of A$1.7 million. The consolidated financial statements
• $75 million — our non-affiliate public float exceeds $75 million. The amount of funds we can raise throu

Filing Documents

• d872361d20f.htm (20-F) — 3055KB
• d872361dex22.htm (EX-2.2) — 49KB
• d872361dex421.htm (EX-4.21) — 59KB
• d872361dex111.htm (EX-11.1) — 96KB
• d872361dex121.htm (EX-12.1) — 10KB
• d872361dex122.htm (EX-12.2) — 10KB
• d872361dex131.htm (EX-13.1) — 6KB
• d872361dex151.htm (EX-15.1) — 2KB
• d872361dex152.htm (EX-15.2) — 2KB
• d872361dex971.htm (EX-97.1) — 28KB
• g872361g1029115046252.jpg (GRAPHIC) — 3KB
• g872361g1106090420108.jpg (GRAPHIC) — 37KB
• 0001193125-24-259805.txt ( ) — 15022KB
• kzia-20240630.xsd (EX-101.SCH) — 147KB
• kzia-20240630_cal.xml (EX-101.CAL) — 59KB
• kzia-20240630_def.xml (EX-101.DEF) — 448KB
• kzia-20240630_lab.xml (EX-101.LAB) — 721KB
• kzia-20240630_pre.xml (EX-101.PRE) — 618KB
• d872361d20f_htm.xml (XML) — 3107KB

tem 18

Item 17Item 18 If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo Table of Contents TABLE OF CONTENTS

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS 1 PART I 1 Item 1. Identity of Directors, Senior Management and Advisors 1 Item 2. Offer Statistics and Expected Timetable 1 Item 3. Key Information 1 Item 4. Information on the Company 16 Item 4A. Unresolved Staff Comments 31 Item 5. Operating and Financial Review and Prospects 31 Item 6. Directors, Senior Management and Employees 36 Item 7. Major Shareholders and Related Party Transactions 48 Item 8. Financial Information 49 Item 9. The Offer and Listing 49 Item 10. Additional Information 49 Item 11.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 62 Item 12.

Description of Securities Other than Equity Securities

Description of Securities Other than Equity Securities 63 PART II 64 Item 13. Defaults, Dividend Arrearages and Delinquencies 64 Item 14. Material Modifications to the Rights of Security Holders and the Use of Proceeds 64 Item 15.

Controls and Procedures

Controls and Procedures 65 Item 16. [Reserved] 65 Item 16A. Audit Committee Financial Expert 65 Item 16B. Code of Ethics 66 Item 16C. Principal Accounting Fees and Services 66 Item 16D. Exemptions from the Listing Standards for Audit Committees 67 Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers 67 Item 16F. Changes in Registrant's Certifying Accountant 67 Item 16G. Corporate Governance 67 Item 16H. Mine Safety Disclosure 68 Item 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 68 Item 16J. Insider trading policies 68 Item 16K. Cybersecurity 69 PART III 69 Item 17.

Financial Statements

Financial Statements 69 Item 18.

Financial Statements

Financial Statements 69 Item 19. Exhibits 70 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Annual Report on Form 20-F includes forward-looking statements, which involve a number of risks and uncertainties. These forward-looking statements can generally be identified as such because the context of the statement will include words such as "may," "will," "intend," "plan," "believe," "anticipate," "expect," "estimate," "predict," "potential," "continue," "likely," or "opportunity," the negative of these words or other similar words. Similarly, statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects and other statements that are not historical facts are also forward-looking statements. Discussions containing these forward-looking statements may be found, among other places, in "Business Overview" and "Operating and Financial Review and Prospects" in this Annual Report on Form 20-F. For such statements, we claim the protection of the Private Securities Litigation Reform Act of 1995 and section 27A of the Securities Act and Section 21E of the Exchange Act. Readers of this Annual Report on Form 20-F are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the time this Annual Report on Form 20-F was filed with the Securities and Exchange Commission, or SEC. These forward-looking statements are based largely on our expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. These risks and uncertainties include, without limitation, those discussed in "Risk Factors" and in "Operating and Financial Review and Prospects" of this Annual Report on Form 20-F. In addition, past financial or operating performance is not necessarily a reliable indicator of future performance, and you should not use our historical performance to anticipate results or future per

View Full Filing

View this 20-F filing on SEC EDGAR